Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20140121169A1
SERIAL NO

14137256

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SYNERGY PHARMACEUTICALS INC420 LEXINGTON AVENUE SUITE 1609 NEW YORK NY 10170

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jacob, Gary S New York, US 50 1092
Nikiforovich, Gregory St. Louis, US 6 210
Shailubhai, Kunwar Audubon, US 96 1112

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation